J.P. Morgan Healthcare Conference 2025 Corporate Presentation Ben Jameson J.P. Morgan Healthcare Conference 2025 Corporate Presentation Read More »
Potent in vivo CAR T cell generation and durable antitumor activity in preclinical models using VivoVec, a surface-engineered lentiviral vector platform Dan Potent in vivo CAR T cell generation and durable antitumor activity in preclinical models using VivoVec, a surface-engineered lentiviral vector platform Read More »
VivoVec lentiviral vector particles surface-engineered with T cell activating and co-stimulatory ligands enhance in vivo CAR T cell generation and antitumor activity Dan VivoVec lentiviral vector particles surface-engineered with T cell activating and co-stimulatory ligands enhance in vivo CAR T cell generation and antitumor activity Read More »
Synthetic Receptor Enabled Differentiation (ShRED), a novel platform for manufacturing of iPSC-derived cytotoxic innate lymphocytes for “off-the-shelf” cancer immunotherapies Dan Synthetic Receptor Enabled Differentiation (ShRED), a novel platform for manufacturing of iPSC-derived cytotoxic innate lymphocytes for “off-the-shelf” cancer immunotherapies Read More »
In vivo generation of universal CAR T cells that mediate durable anti-tumor immunity through combinatorial targeting with bispecific small molecule adaptors Dan In vivo generation of universal CAR T cells that mediate durable anti-tumor immunity through combinatorial targeting with bispecific small molecule adaptors Read More »
